Htr5A Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Htr5A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The HTR5A gene (5-Hydroxytryptamine Receptor 5A) encodes the serotonin receptor subtype 5-HT5A, a G-protein coupled receptor that primarily signals through Gi/o proteins to inhibit adenylyl cyclase. This receptor is one of the least characterized serotonin receptor subtypes but is increasingly recognized for its roles in circadian rhythm regulation, sleep-wake cycles, learning and memory, and psychiatric disorders. HTR5A has been implicated in Alzheimer's disease, schizophrenia, depression, and sleep disorders.
| Symbol | HTR5A |
| Full Name | 5-Hydroxytryptamine Receptor 5A |
| Chromosomal Location | 7q36.1 |
| NCBI Gene ID | 3367 |
| OMIM | 182134 |
| Ensembl | ENSG00000157219 |
| UniProt | P47864 |
| Protein Length | 357 amino acids |
| Protein Family | GPCR, serotonin receptor family |
The HTR5A gene is located on chromosome 7q36.1 and consists of multiple exons. The coding sequence encodes a 357 amino acid protein belonging to the G-protein coupled receptor superfamily.
- Seven transmembrane domains: Characteristic of GPCRs
- N-terminal extracellular domain: Ligand binding site for serotonin
- C-terminal intracellular domain: G protein coupling and phosphorylation sites
- Conserved DRY motif: Critical for G protein coupling
5-HT5A receptors primarily couple to Gi/o proteins:
- Adenylyl cyclase inhibition: Reduces cAMP production
- MAPK pathway modulation: Affects ERK1/2 signaling cascades
- Ion channel modulation: Can regulate calcium and potassium channels
- β-arrestin recruitment: Mediates GPCR-independent signaling
- Neuronal hyperpolarization: Through GIRK channel activation
- Reduced neuronal excitability: Inhibits action potential firing
- Modulation of neurotransmitter release: Affects GABA, glutamate, and acetylcholine release
- Circadian clock regulation: Influences suprachiasmatic nucleus function
- Hippocampus: High expression in CA1-CA3 and dentate gyrus
- Cerebral cortex: Moderate expression in layers II-III and V
- Cerebellum: Purkinje cell layer
- Suprachiasmatic nucleus (SCN): High expression - key for circadian regulation
- Basal ganglia: Low to moderate expression
- Thalamus: Moderate expression
- Amygdala: Low expression
- Primarily expressed in neurons
- Some expression in astrocytes
- Limited microglial expression
HTR5A is implicated in AD through several mechanisms:
- Sleep disturbances: 5-HT5A in SCN contributes to circadian rhythm disruption common in AD
- Cognitive function: Hippocampal 5-HT5A signaling affects memory consolidation
- Amyloid pathology: Serotonin signaling modulates Aβ production and toxicity
- Circadian dysfunction: Early circadian rhythm disturbances in AD patients involve serotonin signaling
- Depression in AD: 5-HT5A polymorphisms associated with depressive symptoms
- Genetic association: HTR5A variants linked to schizophrenia susceptibility
- Cognitive deficits: 5-HT5A signaling affects prefrontal cortical function
- Treatment response: May influence antipsychotic drug response
¶ Depression and Mood Disorders
- Genetic variants: HTR5A polymorphisms associated with major depression
- SSRIs effect: Chronic SSRI treatment may involve 5-HT5A modulation
- Treatment target: 5-HT5A antagonists being explored as antidepressants
- Circadian regulation: 5-HT5A in SCN critical for circadian rhythm
- Sleep architecture: Affects REM sleep regulation
- Sleep disorders in neurodegeneration: 5-HT5A dysfunction may contribute to sleep disturbances in PD and AD
- Sleep disorders: RBD and insomnia common in PD may involve 5-HT5A
- Mood: Depression in PD associated with serotonin system changes
- Cognition: 5-HT5A modulation affects executive function
- 5-HT5A antagonists: Being developed for depression and cognitive disorders
- 5-HT5A inverse agonists: Potentially useful for sleep disorders
- Allosteric modulators: May provide more selective modulation
- SB-699551: Selective 5-HT5A antagonist
- SB-224289: 5-HT5A inverse agonist
- AS2035878: 5-HT5A antagonist with CNS penetration
- Adjunct therapy for treatment-resistant depression
- Cognitive enhancement in schizophrenia
- Sleep disorder management in neurodegenerative disease
- Anxiety disorders
- Htr5a knockout mice show altered circadian rhythm
- Enhanced hippocampal long-term potentiation observed
- Behavioral phenotypes in anxiety and depression tests
- Reduced responses to serotonergic drugs
- 5-HT5A agonists/antagonists used to study receptor function
- Models of circadian rhythm disruption
- Depression and anxiety models
- Selective agonists: Developing brain-penetrant 5-HT5A agonists for cognitive enhancement
- Crystal structure: Understanding 5-HT5A structure for rational drug design
- Biomarkers: Identifying downstream markers of 5-HT5A activity
- Combination therapy: 5-HT5A modulators with existing treatments
- Genetic studies: Further GWAS to identify disease-associated variants
Htr5A Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Htr5A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Noda M, et al. (2005). "5-HT5A receptors in the central nervous system." Neuropharmacology. 49(2):218-225. PMID:15652373
[2] Yamazaki M, et al. (2014). "5-HT5A receptor regulates circadian rhythm." Journal of Neuroscience. 34(44):14556-14565. PMID:24501350
[3] Liu J, et al. (2011). "Association between HTR5A polymorphisms and depression." Journal of Affective Disorders. 131(1-3):245-251. PMID:21864975
[4] Nelson LE, et al. (2013). "Targeting 5-HT5A receptors for CNS disorders." Pharmacology & Therapeutics. 138(2):260-269. PMID:23665048
[5] Kohen R, et al. (2001). "Cloning and characterization of mouse and human 5-HT5A receptors." Neuropharmacology. 40(4):553-563. PMID:11222068
- Graham DL, et al. (2017). The 5-HT5A receptor and its inhibitors: therapeutic potential in the central nervous system. Pharmacol Rev. 69(3):316-341. PMID:28626069.
- Flores-Gracia C, et al. (2010). 5-HT5A receptors in the central nervous system. Cell Tissue Res. 342(1):1-9. PMID:20848118.
- Osterwald R, et al. (2015). Association of HTR5A gene variants with neuropsychiatric disorders. Mol Psychiatry. 20(9):1052-1061. PMID:25668071.
- Birk A, et al. (2013). 5-HT5A receptor signaling in neuronal plasticity. Neuropsychopharmacology. 38(12):2447-2457. PMID:23787833.
- Vanhoenacker P, et al. (2000). 5-HT7 receptors: current knowledge and prospects for drug development. Prog Drug Res. 55:125-163. PMID:10831786.
- Garcia-Rea K, Le Foll B. 5-HT5A receptor antagonists: a review of current status. Curr Med Chem. 2019;26(18):3319-3332. PMID:30227844.
- Nelson DL. 5-HT5 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3(1):53-58. PMID:14965244.
- Singer JH, Bellingham MC, Berger AJ. Presynaptic inhibition of glutamatergic synaptic transmission to rat motoneurons by serotonin. J Neurophysiol. 2006;96(5):2713-2721. PMID:16885504.
- Watson J, Collin L, Ho G, et al. 5-HT5A receptor signalling in neuronal cells. Neuropharmacology. 2011;61(1-2):42-48. PMID:21324323.
- Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. The 5-HT5A receptor in the central nervous system. Cell Mol Neurobiol. 2006;26(4-6):811-823. PMID:16686855.
The HTR5A gene is located on chromosome 7q36.1 and spans approximately 4.2 kb. It consists of 2 exons encoding a 357-amino acid G-protein coupled receptor. The promoter region contains regulatory elements for neuronal expression, including NRE-1 and NRE-2 motifs. Alternative splicing generates multiple transcript variants with distinct expression patterns.
HTR5A couples primarily to Gi/o proteins, inhibiting adenylyl cyclase and reducing cAMP levels. Key signaling features include Gi/o-mediated inhibition of adenylate cyclase, activation of MAPK pathways (ERK1/2, p38), modulation of ion channels (K+ channels), and beta-arrestin recruitment and signaling. In neurons, 5-HT5A receptors modulate neuronal excitability, regulate neurotransmitter release, influence sleep-wake cycles, and participate in cognitive processes.
5-HT5A receptors represent emerging therapeutic targets. Current drugs including LSD and ergot derivatives have agonist activity, and novel selective agonists and antagonists are in development. Clinical potential exists for sleep disorders, depression, and cognitive enhancement. In neurodegeneration, 5-HT5A modulation may help with sleep disturbances in AD/PD, mood disorders in neurodegenerative disease, and pain processing modulation.
Animal models include knockout mice with altered exploratory behavior and circadian rhythm disruptions, transgenic models with neuronal overexpression studies, and pharmacological models using 5-HT5A agonists and antagonists.
Current research focuses on development of brain-penetrant selective ligands, understanding 5-HT5A in neurodegeneration, the role in memory and learning, and sleep-wake regulation mechanisms.
- [1] Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083-1152. PMID:10462127
- [2] Hranilovic D, et al. Serotonin 5-HT5A receptors in the mammalian brain. J Neural Transm Suppl. 2000;(60):1-16. PMID:10938634
- [3] Garcia-Colunga J, et al. Blockade of 5-HT5A receptors by cyanopindolol. Neuropharmacology. 2001;40(4):562-567. PMID:11297713
- [4] Werner FM, Covenas R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci. 2011;121(2):63-74. PMID:21129912
- [5] Wang R, et al. The role of 5-HT5A receptors in the treatment of Alzheimer's disease. Exp Ther Med. 2017;14(5):4715-4722. PMID:29104651